These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 27173004)
1. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity. Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004 [TBL] [Abstract][Full Text] [Related]
2. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4. Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714 [TBL] [Abstract][Full Text] [Related]
3. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196 [TBL] [Abstract][Full Text] [Related]
4. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors. Kakizawa T; Ota Y; Itoh Y; Suzuki T Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865 [TBL] [Abstract][Full Text] [Related]
5. The future therapeutic potential of histone demethylases: A critical analysis. Natoli G; Testa G; De Santa F Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620 [TBL] [Abstract][Full Text] [Related]
6. Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication. Chakravarty S; Jhelum P; Bhat UA; Rajan WD; Maitra S; Pathak SS; Patel AB; Kumar A Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):152-164. PubMed ID: 27664837 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896 [TBL] [Abstract][Full Text] [Related]
8. Histone H3 peptide based LSD1-selective inhibitors. Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526 [TBL] [Abstract][Full Text] [Related]
10. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Morera L; Lübbert M; Jung M Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667 [TBL] [Abstract][Full Text] [Related]
11. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Murray-Stewart T; Woster PM; Casero RA Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577 [TBL] [Abstract][Full Text] [Related]